[1] Lin Y L, Yao T, Wang Y W, et al. Association between primary biliary cholangitis with diabetes and cardiovascular diseases: a bidirectional multivariable mendelian randomization study[J]. Clin Res Hepatol Gastroenterol, 2024, 48(7): 102419.
[2] Trivedi P J, Hirschfield G M. Recent advances in clinical practice: epidemiology of autoimmune liver diseases[J]. Gut, 2021, 70(10): 1989-2003.
[3] Zeng N, Duan W, Chen S, et al. Epidemiology and clinical course of primary biliary cholangitis in the asia-pacific region: a systematic review and meta-analysis[J]. Hepatol Int, 2019, 13(6): 788-799.
[4] Gershwin M E, Selmi C, Worman H J, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients[J]. Hepatology, 2005, 42(5): 1194-1202.
[5] Liu Y, Han K, Liu C, et al. Clinical characteristics and prognosis of concomitant primary biliary cholangitis and autoimmune diseases: a retrospective study[J]. Can J Gastroenterol Hepatol, 2021, 2021: 5557814.
[6] Floreani A, Franceschet I, Cazzagon N, et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis[J]. Clin Rev Allergy Immunol, 2015, 48(2-3): 192-197.
[7] Jensen A H, Winther-Sørensen M, Burisch J, et al. Autoimmune liver diseases and diabetes: a propensity score matched analysis and a proportional meta-analysis[J]. Liver Int, 2023, 43(11): 2479-2491.
[8] Liu X, Xu H, Zhan M, et al. The potential effects of diabetes mellitus on liver fibrosis in patients with primary biliary cholangitis[J]. Med Sci Monit, 2019, 25: 6174-6180.
[9] Lv D, Wang H, Leng Y, et al. Association between diabetes mellitus and primary biliary cholangitis: a two-sample Mendelian randomization study[J]. Front Endocrinol (Lausanne), 2024, 15: 1362584.
[10] Zhao D T, Yan H P, Han Y, et al. Prevalence and prognostic significance of main metabolic risk factors in primary biliary cholangitis: a retrospective cohort study of 789 patients[J]. Front Endocrinol (Lausanne), 2023, 14: 1142177.
[11] Chen S, Li M Q, Li B E, et al. Concomitant gallstone disease was not associated with long-term outcomes in ursodeoxycholic acid-treated patients with primary biliary cholangitis[J]. J Dig Dis, 2023, 24(6-7): 419-426.
[12] Fletcher B, Gulanick M, Lamendola C. Risk factors for type 2 diabetes mellitus[J]. J Cardiovasc Nurs, 2002, 16(2): 17-23.
[13] Kumar R. Hepatogenous diabetes: an underestimated problem of liver cirrhosis[J]. Indian J Endocrinol Metab, 2018, 22(4): 552-559.
[14] 刘磊. 原发性胆汁性肝硬化合并糖尿病的临床特征研究[J]. 中国实用医药, 2014, 9(23): 53-54.
[15] 张瑢国. 原发性胆汁性胆管炎合并糖尿病的临床研究[D]. 山西医科大学, 2022.
[16] 刘美玲. 原发性胆汁性肝硬化合并糖尿病的临床特征分析[J]. 临床肝胆病杂志, 2011, 27(6): 635-637.
[17] 刘亚文. 原发性胆汁性肝硬化合并2型糖尿病采取中西医结合治疗的效果探究[J]. 糖尿病新世界, 2015(21): 62-63.
[18] 贺蓉. 中西医结合治疗原发性胆汁性肝硬化合并2型糖尿病的临床疗效观察[J]. 实用心脑肺血管病杂志, 2014, 22(11): 126-127.
[19] Zhou W, Anakk S. Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism[J]. Mol Cell Endocrinol, 2022, 549: 111616.
[20] Yan N, Yan T, Xia Y, et al. The pathophysiological function of non-gastrointestinal farnesoid X receptor[J]. Pharmacol Ther, 2021, 226: 107867.
[21] Šarenac T M, Mikov M. Bile acid synthesis: from nature to the chemical modification and synthesis and their applications as drugs and nutrients[J]. Front Pharmacol, 2018, 9: 939.
[22] Brufau G, Stellaard F, Prado K, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism[J]. Hepatology, 2010, 52(4): 1455-1464.
[23] Agmon-Levin N, Theodor E, Segal R M, et al. Vitamin D in systemic and organ-specific autoimmune diseases[J]. Clin Rev Allergy Immunol, 2013, 45(2): 256-266.
[24] Hong F, Xu P, Zhai Y. The Opportunities and challenges of peroxisome proliferator-activated receptors ligands in clinical drug discovery and development[J]. Int J Mol Sci, 2018, 19(8): 2189.
[25] Jensen A H, Ytting H, Winther-Sørensen M, et al. Autoimmune liver diseases and diabetes[J]. Eur J Gastroenterol Hepatol, 2023, 35(9): 938.
[26] Rong G, Wang H, Bowlus C L, et al. Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis[J]. Clin Rev Allergy Immunol, 2015, 48(2-3): 132-141.
[27] Bosch D E, Zen Y, Boukhar S A, et al. Hepatocellular carcinoma in primary sclerosing cholangitis and primary biliary cholangitis: a clinical and pathological study in an uncommon but emerging setting[J]. Virchows Arch, 2021, 479(6): 1131-1143.
[28] Tomiyama Y, Takenaka K, Kodama T, et al. Risk factors for survival and the development of hepatocellular carcinoma in patients with primary biliary cirrhosis[J]. Intern Med, 2013, 52(14): 1553-1559. |
